Table 2.
Diagnostic and CPAP study PSG parameters
| PSG data | Total | Female | Male | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Diagnostic study (n = 149) | CPAP study (n = 149) |
P-value | Diagnostic study (n = 68) | CPAP study (n = 68) |
P-value | Diagnostic study (n = 81) | CPAP study (n = 81) |
P-value | |
| Sleep latency | 14.45 (4.05, 40.5) | 13 (6.45, 27) | 0.260 | 19.5 (4.75, 32.75) | 15.85 (7.8, 29.25) | 0.783 | 12.75 (3.45, 41.75) | 9.9 (5, 21.7) | 0.178 |
| REM latency | 114.5 (82.5, 184.75) | 86.75 (58, 145.75) | 0.008* | 127 (87, 198) | 91.25 (62.75, 128.25) | 0.002* | 106 (76.5, 164.5) | 80.75 (53.25, 150.75) | 0.556 |
| Total sleep time | 384.5 (331, 445) | 347.25 (294.5, 398) | <0.001* | 385.25 (330.5, 450.5) | 345.25 (296, 398) | <0.001* | 382.8 (331, 441.5) | 349.5 (294.5, 399.75) | <0.001* |
| WASO | 66.75 (33.65, 110.25) | 73.3 (37.75, 113.05) | 0.843 | 67 (36.85, 103.5) | 71.25 (37.75, 108.2) | 0.961 | 65.9 (31.6, 117) | 74.05 (39, 116.25) | 0.801 |
| Sleep efficiency | 81.1 (69.8, 88.2) | 79.6 (70.25, 87.8) | 0.373 | 81.15 (70.1, 87.55) | 78.85 (70.8, 88.15) | 0.608 | 81.1 (69.7, 88.2) | 80.9 (69.9, 87.05) | 0.533 |
| N1 stage (%) | 12.5 (7.3, 20.9) | 9.25 (5.95, 14.95) | <0.001* | 10.2 (6.4, 16.9) | 8 (4.5, 11.15) | 0.009* | 15.3 (8.1, 26.1) | 11.45 (7, 17.7) | 0.001* |
| N2 stage (%) | 56 (50.3, 65.5) | 49.7 (41.7, 55.1) | <0.001* | 57.7 (48.25, 64.75) | 47.25 (38.5, 55.65) | <0.001* | 54.3 (50.5, 67.4) | 50.45 (45.35, 54.3) | <0.001* |
| N3 stage (%) | 34.867 (0.7, 15.8) | 17.5 (9.1, 24.65) | <0.001* | 10.2 (4.15, 18.2) | 21.9 (15.5, 28.55) | <0.001* | 4.6 (0, 10.7) | 12.95 (5.55, 21.25) | <0.001* |
| REM (%) | 16.5 (10.2, 21.6) | 22.1 (16.15, 28.4) | <0.001* | 17.65 (11.45, 21.6) | 21.5 (15.7, 28.35) | 0.005* | 15.6 (6.9, 21.8) | 23.1 (16.35, 28.45) | <0.001* |
| RAI | 16.6 (8.4, 38.7) | 4 (1.65, 10.55) | <0.001* | 14.55 (6.9, 30.1) | 2.75 (0.95, 5.4) | <0.001* | 24.6 (10.9, 45.3) | 6.55 (2.55, 18.7) | <0.001* |
| SAI | 2.7 (1.1, 5.9) | 7.25 (4.45, 10.35) | <0.001* | 3.3 (1.8, 5.75) | 6 (4.45, 9.85) | <0.001* | 2 (0.9, 5.9) | 7.5 (4.3, 10.6) | <0.001* |
| TAI | 28.5 (17.6, 48.9) | 16.55 (11.3, 25.55) | <0.001* | 26.15 (15, 42.3) | 13.45 (10.3, 19.25) | <0.001* | 31.5 (18.9, 55.7) | 21.1 (13.7, 31.7) | <0.001* |
| Total AHI | 47.6 (23.7, 70.7) | 8.8 (4.4, 20.2) | <0.001* | 34.4 (19.6, 62.5) | 6.5 (3.15, 14.25) | <0.001* | 54.9 (32.4, 75.8) | 12.1 (5.5, 26.7) | <0.001* |
| NREM AHI | 46.5 (21.15, 71.2) | 8.4 (3.8, 21.8) | <0.001* | 29.35 (15.4, 62.7) | 5.75 (2, 12.6) | <0.001* | 55 (28.8, 76.15) | 11.8 (5, 30.6) | <0.001* |
| REM AHI | 56.1 (25.7, 72.3) | 8.2 (2, 19.6) | <0.001* | 61.3 (34.6, 76.7) | 5.75 (1.2, 19.55) | <0.001* | 47.2 (21.2, 68.6) | 8.6 (2.55, 19.6) | <0.001* |
| OSA | 149 (100%) | 107 (72%) | <0.001* | 68 (100%) | 43 (63%) | <0.001* | 81 (100%) | 64 (79%) | <0.001* |
| Mild | 9 (6%) | 58 (54%) | <0.001* | 8 (12%) | 28 (65%) | <0.001* | 1 (1%) | 30 (47%) | <0.001* |
| Moderate | 38 (26%) | 26 (24%) | 0.826 | 20 (29%) | 10 (23%) | 0.477 | 18 (22%) | 16 (25%) | 0.695 |
| Severe | 102 (68%) | 23 (21%) | <0.001* | 40 (59%) | 5 (12%) | <0.001* | 62 (77%) | 18 (28%) | <0.001* |
| SpO2 (wake) | 95 (93, 96) | 96 (94, 97) | <0.001* | 95 (93, 96) | 96 (94, 97) | 0.001* | 94 (93, 96) | 96 (94, 97) | <0.001* |
| SpO2 (NREM) | 93 (92, 94.5) | 95 (94, 97) | <0.001* | 93.5 (92, 95) | 95 (94, 97) | <0.001* | 93 (91, 94) | 95 (94, 96) | <0.001* |
| SpO2 (REM) | 93 (89, 94) | 95 (94, 97) | <0.001* | 93 (89, 94.5) | 95 (94, 97) | <0.001* | 93 (90, 94) | 96 (94, 97) | <0.001* |
| SpO2 (Total) | 93 (92, 95) | 95 (94, 97) | <0.001* | 94 (92, 95) | 95 (94, 97) | <0.001* | 93 (92, 94.5) | 95 (94, 96) | <0.001* |
| SpO2 (Nadir) | 77 (69, 82) | 85 (79, 90) | <0.001* | 78.5 (70.5, 83) | 85 (80, 90) | <0.001* | 77 (68, 81) | 85 (78, 89) | <0.001* |
P-value obtained via Wilcoxon signed-rank test, or equality of proportions z-test. Data displayed as median (IQR) or number (%).